SCHEMBL21807214

SCHEMBL21807214

CC(=O)Nc1c(Br)ccc(F)c1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.42
IDO1 P14902 2/20 0.40
KCNJ11 Q14654 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA9 Q16790 2/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
HTT P42858 2/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ALDH1A1 P00352 2/20 0.36
MAPT P10636 2/20 0.36
POLB P06746 2/20 0.36
HSD17B10 Q99714 2/20 0.35
GAA P10253 1/20 0.35
PKM P14618 1/20 0.35
ALOX15 P16050 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30262599 0.85 IDO1 (0.43) RXFP1IDO1KCNJ11HDAC1HDAC6
SCHEMBL10129973 0.85 IDO1 (0.43) RXFP1IDO1KCNJ11HDAC1HDAC6
SCHEMBL19331127 0.83 ALDH1A1 (0.38) CA1CA2CA9SMN1; SMN2HTT
SCHEMBL16075172 0.79 ALDH1A1 (0.47) RXFP1HDAC1HDAC6CA1CA2
SCHEMBL2892368 0.79 MAOA (0.42) KCNJ11HDAC1HDAC6CA1CA2
SCHEMBL16240385 0.78 HDAC1 (0.48) RXFP1KCNJ11HDAC1SMN1; SMN2HTT
SCHEMBL30954548 0.78 HDAC1 (0.48) RXFP1KCNJ11HDAC1SMN1; SMN2HTT
SCHEMBL22642784 0.78 HDAC1 (0.48) HDAC1HDAC6CA1CA2CA9
SCHEMBL19000145 0.77 GAA (0.40) RXFP1IDO1CA1CA2CA9
SCHEMBL8580592 0.76 MAP2K1 (0.50) HDAC1SMN1; SMN2MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. 2023-03-02 US disclosed
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. 2023-03-02 US disclosed
EP-3852790-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X Forma Therapeutics, Inc. (US) 2021-07-28 EP disclosed
CN-113164571-A Inhibition of ubiquitin-specific peptidase 9X 福马治疗股份有限公司 2021-07-23 CN disclosed
WO-2020061261-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. (US) 2020-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X USP9X, USP19, USP39 RXFP1 3888/4885IDO1 2031/4885KCNJ11 4878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.